Melanin-Concentrating Hormone (MCH) is one of the most relevant orexigenic factors specifically located in the lateral hypothalamic area (LHA), with its physiological relevance demonstrated in studies using several genetically manipulated mice models. However, the central mechanisms controlling MCHinduced hyperphagia remain largely uncharacterized. Here, we show that central injection of MCH in mice deficient for kappa opoid receptor (k-OR) failed to stimulate feeding. To determine the hypothalamic area responsible for this MCH/k-OR interaction, we performed virogenetic studies and found that downregulation of k-OR by adeno-associated viruses (shOprk1-AAV) in LHA, but not in other hypothalamic nuclei, was sufficient to block MCH-induced food intake. Next, we sought to investigate the molecular signaling pathway within the LHA that mediates acute central MCH stimulation of food intake. We found that MCH activates k-OR and that increased levels of phosphorylated extracellular signal regulated kinase (ERK) are associated with downregulation of phospho-S6 Ribosomal Protein. This effect was prevented when a pharmacological inhibitor of k-OR was co-administered with MCH. Finally, the specific activation of the direct upstream regulator of S6 (p70S6K) in the LHA attenuated MCHstimulated food consumption. Our results reveal that lateral hypothalamic k-OR system modulates the orexigenic action of MCH via the p70S6K/S6 pathway.
Introduction
In mammals, MCH is a cyclic 19-amino acid neuropeptide synthesized in the LHA and zona incerta (ZI). This neuropeptide is a critical hypothalamic regulator of energy homeostasis, having effects on both feeding behavior and energy expenditure. Central administration (Qu et al., 1996) , or transgenic overexpression (Ludwig et al., 2001 ) of MCH increases food intake, whereas deletion of MCH (Alon and Friedman, 2006; Shimada et al., 1998) or its receptor (Chen et al., 2002) reduces body weight. In addition, MCH can modulate glucose metabolism (Kong et al., 2010; Ludwig et al., 2001 ) and peripheral lipid metabolism in the white adipose tissue (Imbernon et al., 2013) and liver (Imbernon et al., 2016; Pissios et al., 2006) . Although it is well recognized that MCH acts in a way to preserve energy, the molecular mechanisms underlying MCH action are poorly understood. Previous studies indicate that MCH acts in concert with other neuropeptides, such as NPY or POMC in the arcuate nucleus (ARC) (Griffond and Risold, 2009) , and orexin in LHA (Guan et al., 2002) . However, there is a general lack of information regarding the interaction with other hypothalamic systems. Opioid receptors are widely expressed within the hypothalamus (Mansour et al., 1994) , and we have previously demonstrated that the k-OR system in the ARC is able to modulate the orexigenic effect of ghrelin (Romero-Pic o et al., 2013) . A potential interaction among MCH and the opioid system to regulate food intake and food addiction was postulated previously (Lopez et al., 2011) , but the mechanistic aspects and the specific brain areas where this interaction occurs remain unexplored. Since LHA seems to be a link between homeostatic and hedonic centers controlling feeding behavior, and k-OR co-localizes with MCH receptor in the LHA (Imbernon et al., 2016) , we investigated whether MCH may act via the opioid system within this hypothalamic area to drive acute food consumption.
Here we use multiple pharmacological and genetic approaches to provide evidence that MCH-induced food intake is mediated through the activation of k-OR signaling specifically within the LHA. This MCH/k-OR interaction involves reduced phospho-S6, and the functional relevance of this mechanism was demonstrated by the fact that genetic constitutive activation of p70S6K in the LHA blocked MCH-induced feeding. These results confirm the relevant role of the hypothalamic kappa opioid system as a modulator of MCH orexigenic effect, positioning k-OR as a common neuronal signaling pathway integrating central orexigenic signals.
Material and methods

Animal procedures and chemicals
Male Sprague-Dawley rats (200-250 g) were housed individually and maintained on 12:12-h light-dark cycle at constant temperature (21±1 C) and humidity (40-50%). They were allowed ad libitum access to water and standard chow from Scientific Animal (proteins 16%, carbohydrates 60%, and fat 3%). In all procedures implying surgery, rats were anesthetized by an intraperitoneal injection of ketamine-xylacine (ketamine 100 mg/kg BW þ xylazine 15 mg/kg BW).
Adult (8-10 weeks old) wild type (WT) C57BL6 mice, mutant mice (Oprk1
) that lack functional k-OR subtype 1 (B6.129S2-Oprk1 tm1kff /J, The Jackson Laboratory) (Imbernon et al., 2016; Romero-Pic o et al., 2013) , were maintained on an ad libitum chow diet in Specific Pathogen Free (SPF) conditions and housed with a 12:12-h light-dark cycle. For surgery, mice were anesthetized by an intraperitoneal injection of 138 mg ketamine/Kg BW þ 7 mg xylacine/Kg BW. Intracerebroventricular (i.c.v.) central injections were performed between 9:00-10:00 am. All animal procedures were conducted in accordance with the standards approved by the Faculty Animal Committee at the University of Santiago de Compostela, and experiments were performed in agreement with the rules of Laboratory Animal Care and International Law on Animal Experimentation. Opioid receptors antagonists: naloxone hydrochloride (nonselective) and norBNI (nor-Binaltorphimine dihydrochloride), a selective k-OR antagonist were purchased by Tocris (St Lois, MO, USA). Melanin-Concentrating Hormone (MCH, H-1482) was provided by Bachem (Bubendorf, Switzerland).
Pharmacological studies
Two different approaches were addressed in this study. First, to identify MCH targets we used two groups: 1) control rats (i.c.v. vehicle) and 2) MCH treated rats (i.c.v. MCH). Second, to study the effect of opioid receptor antagonists on acute MCH-induced food intake, rats were fed ad libitum and organized in three groups (n ¼ 10/per group) receiving double i.c.v. injection: 1) vehicle þ vehicle; 2) vehicle þ MCH; 3) opioid receptor antagonist þ MCH. I.c.v. cannulae aimed at the lateral ventricle were implanted as describe previously (Romero-Pic o et al., 2013) . After 5 days of recovery, opioid receptor antagonist was administered i.c.v. 20 min prior MCH injection. The doses employed to inhibit total opioid receptors (naloxone) and k-OR (norBNI) was 75 nmol and 40 nmol, respectively (Romero-Pic o et al., 2013) . The dose of MCH utilized to stimulate acute food intake at 2 h was 8.4 nmol/rat in 5 ml. WT and OprkÀ/À mice (n ¼ 8 per group) received a single injection of vehicle or MCH (4.2 nmol/mouse in 2 ml) as previously described (Imbernon et al., 2016) . We measured food intake over 2 h and then animals were sacrificed and brains frozen at -80 C. For molecular studies in rats, we sacrificed the animals at 15, 30, 90 or 120 min and froze the brains at -80 C until nuclei isolation.
Genetic approaches
We used adeno-associated viruses (AAV) encoding scramble or short hairpin kappa opioid receptor subtype 1 mRNA (shOprk1) as previously described (Imbernon et al., 2016; Romero-Pic o et al., 2013) . Stereotaxic injections of AAV into specific brain areas were carried out using previously established coordinates (Imbernon et al., 2016; Romero-Pic o et al., 2013) : PVH (±0.5 mm from the midline, 1.9 mm posterior to bregma, and 8 mm ventral from the surface of the skull); ARC (±0.3 mm lateral, -2.8 mm anteroposterior, and 10.2 mm dorso-ventral); LHA (±2 mm lateral, -2.85 mm antero-posterior, and 8.1 mm dorso-ventral). For each nucleus studied we set up four groups (n ¼ 10 rats/per group): 1) scramble-AVV þ vehicle i.c.v.; 2) scramble-AAV þ MCH i.c.v.; 3) shOprk-AAV þ vehicle i.c.v.; 4) shOprk-AAV þ MCH i.c.v. 15 days after the stereotaxic surgery, an i.c.v. cannula was implanted in the lateral ventricle and 5 days later, we administered vehicle (saline) or MCH i.c.v. and measured food consumption at 2 h. Then, rats were sacrificed and brains were frozen at -80 C.
We utilized null adenoviruses (Control-Ad) or adenoviruses encoding a constitutively active p70S6Kinase form (CAS6K-Ad) (Blouet et al., 2008) to study the molecular cascade involved in MCH action. Plasmid pRK7-HA-S6K1-F5A-E389-R3A was courteously gift by Dr. Cl emence Blouet. Cloning and package in Ad5-CMV-GFP adenoviruses was performed at Viral Vector Production Unit (Universitat Aut onoma de Barcelona). Four groups (n ¼ 10 rats per group) were subjected to stereotaxic surgery:
Adenoviruses were bilaterally injected in the LHA (±2 mm lateral, -2.85 mm anteroposterior, and 8.1 mm dorso-ventral). One week after surgery, an i.c.v. cannula was implanted and 5 days later we i.c.v. injected vehicle or MCH. At 2 h, we measured food intake and rats were sacrificed and brains were stored at -80 C until analysis.
RNA isolation and TaqMan
Total RNA isolation from PVH, ARC, and LHA was performed following TRIZOL Reagent manufacture's protocol. Reverse transcriptase (RT) and real-time PCR (TaqMan) were done as previously described (L opez et al., 2008) . Primers used in this study are depicted in Table I (Supplementary information).
Western blot
Total protein extract was obtained from LHA using lysis buffer (50 mM Tris-HCl pH ¼ 7.5, 1 mM EGTA, 1 mM EDTA, 1% Triton-X100, 1 mM Sodium Orthovanadate, 50 mM Sodium Fluoride, 5 mM Sodium Pyrophosphate, 0.27 M sucrose). We charged 20 mg of total protein in 8e10% SDS-PAGE acrylamide gels. Proteins were transferred to Immuno-Blot PVDF membranes (BIORAD) with 0.2 or 0.45 mg pore size. The membranes were subsequently blocked with 3e5% BSA in TBS 0.1% tween (TBS-T) for 1 h. Membranes were incubated overnight with primary antibodies in blocking solution at 1:1000 dilution: goat anti-k-OR (Sigma SAB2501442), rabbit anti-phospho-ERK (Cell Signaling #4370), rabbit anti-p70S6Kinase (Cell Signaling #9202), rabbit antiphospho-S6 ribosomal protein (Ser235/236) (Cell Signaling #2211), mouse anti-S6 ribosomal protein (Cell Signaling #2317) and mouse anti-b-Actin (Sigma A5316). Afterwards, membranes were washed three times 10 min with TBS-T, incubated 1 h with secondary antibodies (DAKO) at 1:5000 dilutions, and again washed before protein detection using ECL chemiluminescent western blot substrate (Thermo Scientific). Images were quantified by ImageJ software.
Immunohistochemistry and GFP visualization
Brains were fixed in 4% formaldehyde calcium. Paraffinembedded coronal brain sections (5 mm) were dried overnight at 55-60 C, de-paraffined with xylene and then rehydrated. Antigenic recuperation was performed incubating 20 min at 97 C in a 10 mM Tris-EDTA buffer. For immunohistochemistry (IHC), sections were incubated overnight at 4 C with goat anti-k-OR receptor (Sigma SAB2501442) diluted 1:3000, rabbit antiphospho-S6 (Cell Signaling #2211) (1:200), or rabbit antip70S6Kinase (Cell Signaling #9202) (1:100) in EnVision Flex Antibody diluent (DAKO). After three washes, sections were incubated with LSAB-DAKO secondary for 30 min. Images were captured in a conventional microscopy (Olympus XC50). Quantification of phospho-S6 immuno-positive signal was performed through Frida software.
Immunofluorescence was destined to test specific nuclei injection and co-localization studies. Sections were incubated with rabbit antibody against green fluorescent protein (GFP) (Abcam ab290) (1:1000), goat anti-k-OR receptor (Sigma SAB2501442), or rabbit anti-MCHR (Abnova PAB16225). To visualize green positive signal, we used a goat anti-rabbit Alexa 488 (for GFP) or donkey anti-goat Cy2 (for k-OR) as secondary antibodies (1:500). To visualize red positive signal, we used donkey anti-rabbit Cy3 (for MCHR) (Jackson ImmunoResearch laboratories, UK). Images were captured in a confocal microscopy (Leica TCS-SP2).
Statistical analysis and data presentation
Results are expressed as mean ± SEM. GraphPad Prism (version 4.0) was used for the data analysis. Comparison between two groups was performed using an unpaired t-test. One-way ANOVA followed by Bonferroni's multiple comparison test was used to compare three treatments (vehicle, MCH, and norBI þ MCH). Twoway ANOVA was used to examine interactions between variables (k-kOR silencing x MCH or S6K activation x MCH effect) followed by a Bonferroni's post-hoc test. Sample size and statistical values are defined in each figure legend. P < 0.05 was considered statistically significant.
Results
Pharmacological or genetic inhibition of the k-OR system blunts MCH-orexigenic effect
Central MCH administration in rats significantly increased food intake after 2 h (vehicle vs MCH, p < 0.01) ( Fig. 1A and B) . The orexigenic effect of MCH was completely blocked by the general opioid receptor antagonist naloxone (75 nmol) (MCH vs MCH þ naloxone, p < 0.001) (Fig. 1A ). This effect was likely mediated by the k-OR receptor since the specific opioid receptor antagonist norBNI (40 nmol) significantly blocked the hyperphagic action induced by MCH at 2 h to similar extent (MCH vs norBNI þ MCH, p < 0.05) (Fig. 1B) .
Dose of antagonists used were chosen based on a dose-and time-response experiment. We found that 30 mg/rat (equivalent to 75 nmol naloxone and 40 nmol norBNI) (i.c.v.) is the minimal amount required to significantly reduce food intake over 1-2 h in fasted rats (Supplementary Figs. S1A and S1B). In our experimental model, we did not include a treatment group with naloxone or norBNI alone, without co-injection of MCH, since it was previously demonstrated by our group that under the same experimental conditions, the non-selective inhibition of opioid system with naloxone, or the pharmacological inhibition of k-OR using norBNI have not a per se effect on food intake during the acute measurement of food consumption (2 h) (Romero-Pic o et al., 2013).
Naloxone and norBNI were delivered 20 min prior to MCH administration. It has been shown, that at 20 min, i.c.v. norBNI produces transient effects at both mu-and delta-receptors (Horan et al., 1992) . Since norBNI is a long-lasting antagonist (up to 3 weeks in vivo) (Bruchas et al., 2007) , we hypothesized that if the effects of norBNI mediating MCH-induced food intake were specific, the injection of norBNI 24 h prior to MCH administration would recapitulate its response. We found that identically to 20 min prior to MCH injection, norBNI injected 24 h prior to MCH blunted its orexigenic action ( Supplementary Fig. S2 ). Moreover, this additional experiment reinforces the fact that norBNI per se has not an anorectic effect 2 h after i.c.v.
In order to confirm the physiological relevance of the k-OR system on acute MCH-induced feeding, we i.c.v. administered MCH in mice lacking functional k-OR. We found that contrary to the orexigenic effect of i.c.v. MCH in wild type mice, MCH was not able to stimulate food intake in OprkÀ/À mice (Fig. 1C ). These results demonstrate that MCH needs a functional central k-OR system to stimulate food consumption.
The functional interaction between MCH and k-OR occurs in the LHA
Recent data have shown that MCHR/k-OR receptors are coexpressed in LHA (Imbernon et al., 2016) . To investigate if this coincidence was restricted to the LHA or it could be found in other hypothalamic sites, we performed double IHC of MCHR and k-OR. Our data showed strong co-localization of both receptors in the ARC (Fig. 1D-F ) and the PVH (Fig. 1G-I ). Besides this morphological evidence, to evaluate the specific hypothalamic nucleus responsible of the MCH-k-OR interaction, we stereotaxically delivered AAV encoding a shRNA against k-OR (shOprk1) in those places ( Fig. 2A) . Infection efficiency was assessed by expression of GFP (Fig. 2B-D) and decreased k-OR levels in the PVH (Fig. 2E and F) , LHA ( Fig. 2G and H), and ARC (Fig. 2I) . To exclude any shRNA-induced saturation of endogenous neuronal microRNAs pathway potentially masking our results, we analyzed mRNA expression of mir124 and mir138 in LHA, two markers of toxicity (Van Gestel et al., 2014) . No changes were observed in the expression of mir124 and mir138 after the knockdown of Oprk1 in the LHA compared to AAV encoding scramble shRNA, indicating that the use of shOprk1-AAV is a viable strategy for mRNA Oprk1-silencing (Fig. 2J) . Of note, we have previously demonstrated that this shRNA for k-OR does not affect expression of the other opioid receptors, supporting the specificity of this knockdown (Romero-Pic o et al., 2013) .
Then, we analyzed the acute effect of MCH i.c.v. on food intake, and expected we found that cumulative food intake was significantly increased in Control-AAV animals. The orexigenic action of MCH i.c.v. was maintained when k-OR was down-regulated in the ARC or PVH (Fig. 2K) . However, when k-OR was down-regulated in the LHA, we observed a significant interaction between k-OR silencing and MCH orexigenic response (P interaction ¼ 0.0121, F ¼ 7.106, DF ¼ 1). While control rats treated with MCH showed a marked hyperphagia during the 2 h period post-injection (P vh vs MCH <0.0001), MCH-induced food intake was significantly decreased when we knocked down the k-OR specifically in LHA (P MCH vs shOprk/MCH ¼ 0.0087) (Fig. 2K) . These results suggest that k-OR signaling in the LHA is essential for the effect of MCH on feeding.
MCH increases phosphorylated levels of ERK in the LHA
Once we had established that k-OR located in the LHA was contributing to MCH-induced hyperphagia, we investigated the downstream molecular mechanisms involved in the interaction between MCH and k-OR within the LHA. Since the inhibition of k-OR affects the orexigenic MCH response, we postulated that the kappa opioid system might act downstream MCH signaling.
First, we corroborated the accuracy of nuclei isolation by assessing the mRNA expression of specific markers, namely proopiomelanocortin (POMC) in the ARC, corticotropin-releasing hormone (CRH) in the PVH, and proOrexin in the LHA ( Supplementary  Fig. S3 ).
k-OR activation is known to activate extracellular signalregulated kinase (ERK), the c-Jun N-terminal kinase (JNK), and p38 MAPK in vitro and in vivo (Bruchas and Chavkin, 2010) . Since the best characterized opioid-induced Mitogen-Activated Protein Kinases (MAPK) network to date is ERK1/2, we analyzed the activity of ERK under central MCH stimulation. We observed that MCH (A-B) rats was analyze by one-way ANOVA followed Bonferroni's multiple comparisons, while food consumption in (C) mice was evaluated by a student t-test. * represents differences compared to vehicle and # indicates differences compared to MCH-treated animals.
induced the phosphorylation of ERK in the LHA at 15 min (p < 0.05) (Fig. 3A) . This molecular effect was transient, with the molecular changes not detected at 30 or 120 min. Thus, the rapid phosphorylation of ERK in the LHA after 15 min i.c.v. MCH injection denotes an activation of k-OR system by MCH. The increased levels of phospho-ERK were accompanied by reduced ribosomal S6 activity in LHA (Fig. 3B) , since rats treated with MCH showed a significant reduction of phosphorylated-S6 form in the LHA, an effect absent after 90 min (Fig. 3C-I) .
Activation of p70S6Kinase in LHA impairs MCH orexigenic effect
If the hypothesis that MCH acts in the LHA by attenuating the S6 activity is correct, the activation of its direct upstream regulator would be expected to block the orexigenic effect of MCH. In order to test this idea, we injected an adenovirus encoding a constitutive active form of p70S6K (CAS6K-Ad) in the LHA (Fig. 1A) . We confirmed the efficiency of the viral vector by detecting increased mRNA Oprk1 or protein expression of k-OR after shOprk-AAV injections in LHA measured by (G) TaqMan and (H) western blot (n ¼ 8 per group). (I) mRNA Oprk1 levels in ARC following injection of either Control-AAV or shOprk1-AAV into this nucleus (n ¼ 8 per group). (J) mir124 and mir138 mRNA expression in LHA to test the viability of shOprk-AAV once targeted into the LHA (n ¼ 8 per group). (K) Food intake stimulated by MCH (8.4 nmol) in rats at 2 h under specific silencing of k-OR into the PVH (n ¼ 10 per group), ARC (n ¼ 10 per group), or LHA (n ¼ 20 per group). Values are expressed as means ± SEM. Student t-test was performed to (E-I) confirm significant reduction of k-OR receptor, or (J) assay mir124 and mir138 expression. Two-way ANOVA followed by Bonferroni's multiple comparison test was used to evaluate the interaction MCH/k-OR system on food consumption. a ¼ MCH orexigenic effect (p < 0.001), b ¼ shOprk-AAV knockdown effect, and c ¼ significant MCH/shOprk-AAV kockdown interaction (p < 0.05) in (K) rats stereotaxically treated with either Control-AAV or shOprk-AAV in LHA.
p70S6K protein levels in the LHA 12 days after administration of CAS6K-Ad compared to control rats (Fig. 4B-D) . Although the highest expression of p70S6K was detected at day 12, activation of p70S6K was significant from day 4 (Fig. 4E) . Next, we i.c.v. administered vehicle or MCH (8.4 nmol) in rats previously injected with either Control-Ad or CAS6K-Ad in LHA, and we found that the activation of p70S6K in the LHA attenuated MCH-induced food intake (P MCH and CAS6K interaction ¼ 0.009, F ¼ 7.646, DF ¼ 1) (Fig. 4F) . A post-hoc test indicated that CAS6K-Ad rats stimulated with MCH ate significantly less than control-MCH animals (p < 0.05).
At the molecular level, we confirmed the up-regulation of p70S6K form in the LHA under CAS6K-Ad activation (p < 0.001) (Fig. 4G) . On the other hand, to further validate the overexpression model we checked the direct downstream target of p70S6K. The ratio phospho-S6/S6 increased when p70S6K was constitutively activated under MCH i.c.v. stimulation (p < 0.05) (Fig. 4H) .
Discussion
Molecular/synaptic mechanisms of how MCH controls feeding have previously been detailed by the DiLeone group (Georgescu et al., 2005; Sears et al., 2010) . They demonstrated that MCH regulates glutamate receptor activity in the nucleus accumbens (NAc), where it acts to modulate feeding behavior. However, within the hypothalamus the molecular mechanisms responsible of MCH-induced orexigenic response are not resolved. Here, in keeping with previous findings (Lopez et al., 2011) , we observe that central non-selective pharmacological inhibition of the opioid system with naloxone impairs acute MCH-induced appetite. Furthermore, our results also document that the kappa opioid system located in LHA plays an important role in modulating the MCH-mediated orexigenic response in rats. Certainly, the degree of blockade observed for virogenetic-induced knockdown of k-OR in the LHA was lower than for the i.c.v. pharmacological blockade. This observation was somewhat expected since it is well known that a lower number of neurons are affected by the virogenetic approach. Moreover, we cannot rule out a potential extrahypothalamic MCH action through k-OR system. Indeed, a good candidate is the NAc where MCHR1 is strongly expressed. Further studies to address this issue are clearly merited. Whatever the explanation, our data conclusively show that within the LHA the mechanism of action of MCH involves the hypothalamic k-OR system and led us to hypothesizes that that k-OR system may play an important role modulating the acute MCH orexigenic response similarly to what occurs with ghrelin in ARC. Noteworthy, we previously demonstrated that the blockade of k-OR signaling in ARC is sufficient to interfere with the orexigenic ghrelin response mediated by NPY in an AMPK-independent manner (Romero-Pic o et al., 2013).
The role of the opioid system on feeding regulation is well established (Bodnar, 2015; Gosnell et al., 1986; Nogueiras et al., 2012) . Within the mesolimbic dopamine reward system, opioids promote appetite for palatable foods through the ventral tegmental area (VTA) and the NAc network (Noel and Wise, 1995) . Besides the hedonic aspects of feeding regulation by the opioid system, opioid receptors are widely expressed in the hypothalamus (Mansour et al., 1994) and interact with homeostatic signals to control food intake. Indeed, the cross-talk between the opioid system and ARC neuropeptides, such as POMC (Pennock and Hentges, 2011) , AgRP (Hagan et al., 2001) , and NPY (Kotz et al., 1993; Schick et al., 1991) has been previously described. MCH receptors and k-OR are colocalized in different hypothalamic areas including ARC, PVN, and For all pairwise comparisons a (A) student t-test was used, whereas in cases with three groups, a (C-I) one-way ANOVA followed Bonferroni's multiple comparisons were used. * indicates differences compared to vehicle and # indicates differences compared to MCH-treated animals.
LHA, however we found that MCH-induced hyperphagia was prevented by genetic inhibition of Oprk1 only in LHA, indicating that this hypothalamic area is the most relevant for MCH/k-OR interaction in terms of food intake. Nevertheless, it is becoming clear that the functional interaction of the k-OR-and MCH-systems is likely to go further than the effect described here. The presence of k-OR in MCH neurons indicates that the activity of MCH neurons is also regulated by endogenous opioid-neurons. In fact it is known that dynorphin neurons are co-localized with MCHR1 neurons (Chee et al., 2013) and that k-OR is co-localized with MCH neurons (Parks et al., 2014) . These anatomical and biochemical findings imply strong functional relationships between the two systems. Further studies assessing the role of the k-OR as a potential mediator of MCH in other brain systems like dopaminergic reward areas such as the NAc and VTA are warranted. Similarly, the functional significance of the k-OR in MCH neurons and putative regulation by endogenous opioid peptides needs to be uncovered.
The LHA is historically considered as a feeding center that connects the homeostatic circuitries to the hedonic ones (Castro et al., 2015) . While MCH is mainly produced in the LHA, MCH neurons project to numerous hypothalamic and extrahypothalamic areas, where MCHR is expressed at the postsynaptic level. Thus, MCH does seem to have a role in the LHA through its interaction with k-OR system, despite the low levels of MCH receptors detected in this area (Chee et al., 2013) . Although we found a clear crosstalk between MCH and k-OR in the LHA, we cannot rule out that this interaction may also cause molecular changes on extra-hypothalamic nuclei to where MCH neurons project, such as VTA or NAc. Further experiments are necessary to answer these questions and to elucidate the whole MCH neuronal network. Importantly, our data show that the MCH/k-OR crosstalk reaches the physiological target of the growth factor-activated p70S6K, namely the 40S subunit of the S6 ribosomal protein that play a key role in modulating translational efficiency. The phosphorylation of S6 ribosomal protein is a valuable hallmark of neuronal activity and by a Bonferroni's Multiple Comparison test was used to (F) evaluate the interaction between CAS6K activation and MCH orexigenic effect. a ¼ MCH significant effect, and c ¼ significant interaction. Student's t-test analysis was used to evaluate (E) the expression of p70S6K over 12 days in rats treated with CAS6K-Ad compared to control rats, and (G, H) the activation of p70S6K/S6 pathway in CAS6K-Ad rats compared to Control-Ad animals. P < 0.05 was considered statistically significant (*p < 0.05, **p < 0.01, ***p < 0.001) compared to Control-Ad group. its biological role in the brain is one of the major challenges nowadays. p70S6K possesses autoinhibitory and catalytic domains. Activation of p70S6K occurs through a complex series of phosphorylation events on eight or more serine or threonine residues. As reviewed by Dufner and Thomas (1999) , these phosphorylation sites are S404, S411, S418, S424 and T421 on the C-terminal autoinhibitory domain and T229, S371 and T389, which are critical for catalytic activity. Autoinhibitory sites, on the other hand, are thought to be phosphorylated by members of the mitogenactivated protein kinase (MAPK) family, p38 and ERK (Mukhopadhyay et al., 1992) and elicit a conformational change to facilitate phosphorylations in the catalytic domain. Previous studies linked ERK with the regulation of S6K (Lee et al., 2016) . Although these studies were undertaken in a different context, during dopaminergic neuronal differentiation of human neuronal stem cells, the authors observed that the increase in phospho-ERK was accompanied by a reduction in phospho-p70S6K. Conversely, inhibition of ERK significantly increased the levels of phosphop70S6K without activation of Akt and mTOR, indicating that ERK might directly inhibit p70S6K. Due to the complexity of p70S6K activity, we decided to focus on its direct downstream target in order to identify if k-OR activation by MCH and increased phosphorylated ERK (phospho-ERK) levels would imply changes in the active (phosphorylated) form of S6. Our results show that in vivo the increased level of phospho-ERK induced by i.c.v. MCH administration was accompanied by a significant reduction of phospho-S6 protein levels at 15 min. This observation also suggests that p70S6K is regulated by ERK signaling pathway during the acute control of food intake in vivo studies. This rapid response mediated by the activation of k-OR might trigger other molecular cascades to regulate food consumption since the highest orexigenic physiological response induced by MCH is observed at 2 h where molecular changes in phospho-ERK and phospho-S6 are absent. Nevertheless, this is the first report of the link between hypothalamic k-OR activation and the regulation of p70S6K pathway through MCH in the central nervous system (CNS), demonstrating the crosstalk between ERK and S6 during acute food intake regulation mediated by MCH.
Finally, it has been previously reported that depression of p70S6K pathways in the mediobasal hypothalamus (MBH) during fasting promotes cellular mechanisms to stimulate appetite whereas the specific activation of p70S6K reduces food intake and protects against the adverse effects of a high fat diet (Blouet et al., 2008) . Our findings indicate that the activation of p70S6K in LHA decreases the food intake promoted by MCH, thus providing additional evidence of the relevance of this kinase on the control of appetite.
Conclusion
In summary, we here describe a novel interaction by which the ERK and p70S6K/S6 cascades are modulated by MCH through k-OR activation during the acute MCH-induced orxigenic response. We found that (a) administration of MCH rapidly activates k-OR in the LHA and increases phospho-ERK protein levels; (b) elevated phospho-ERK levels reduce S6 activity in this area; and (c) at the functional level, constitutively activation of S6 upstream kinase (p70S6K) in LHA significantly decrease the acute food intake induced by MCH. Thus, our findings indicate that k-OR integrates central MCH signaling with the p70S6K/S6 pathway to regulate the action of MCH on acute food intake regulation (Fig. 5) .
Taking into account that MCH plays a major role in the control of energy homeostasis, and that MCH receptor antagonists are in the pipeline of several pharmaceutical companies, our data support the relevance of the hypothalamic kappa opioid system as a potential drug target. In keeping with this, the recent approval of nonselective opioid receptor antagonists for treatment of obese patients adds translational value to our findings. 
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Supplementary data related to this article can be found at https://doi.org/10.1016/j.neuropharm.2017.11.040. Fig. 5 . Scheme summarizing the mechanism of action used by MCH in the LHA to regulate the acute food intake. (A) i.c.v. MCH administration rapidly activates k-OR by enhancing phospho-ERK, and the activation of k-OR has an inhibitory effect on p70S6K/S6 pathway leading to an increase of food intake over 2 h. The reduction of appetite caused by (B) pharmacological inhibition of k-OR (norBNI) or (C) CAS6K-Ad activation in LHA demonstrate a crosstalk between the physiological orexigenic response of MCH and these two systems.
